{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Sone JY"],"funding":["NICHD NIH HHS","NINDS NIH HHS"],"pagination":["2944-2956"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8756480"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["41(11)"],"pubmed_abstract":["Cavernous angiomas with symptomatic hemorrhage (CASH) have a high risk of rebleeding, and hence an accurate diagnosis is needed. With blood flow and vascular leak as established mechanisms, we analyzed perfusion and permeability derivations of dynamic contrast-enhanced quantitative perfusion (DCEQP) MRI in 745 lesions of 205 consecutive patients. Thirteen respective derivations of lesional perfusion and permeability were compared between lesions that bled within a year prior to imaging (N = 86), versus non-CASH (N = 659) using machine learning and univariate analyses. Based on logistic regression and minimizing the Bayesian information criterion (BIC), the best diagnostic biomarker of CASH within the prior year included brainstem lesion location, sporadic genotype, perfusion skewness, and high-perfusion cluster area (BIC = 414.9, sensitivity = 74%, specificity = 87%). Adding a diagnostic plasma protein biomarker enhanced sensitivity to 100% and specificity to 85%. A slightly modified derivation achieved similar accuracy (BIC = 321.6, sensitivity = 80%, specificity = 82%) in the cohort where CASH occurred 3-12 months prior to imaging after signs of hemorrhage would have disappeared on conventional MRI sequences. Adding the same plasma biomarker enhanced sensitivity to 100% and specificity to 87%. Lesional blood flow on DCEQP may distinguish CASH after hemorrhagic signs on conventional MRI have disappeared and are enhanced in combination with a plasma biomarker."],"journal":["Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism"],"pubmed_title":["Perfusion and permeability as diagnostic biomarkers of cavernous angioma with symptomatic hemorrhage."],"pmcid":["PMC8756480"],"funding_grant_id":["R01 NS107887","U01 NS104157","R21 NS087328","T32 HD007009"],"pubmed_authors":["Girard R","Romanos SG","Hobson N","Moore T","Li Y","Piedad K","Srinath A","Bi D","Stadnik A","Awad IA","Shenkar R","Sone JY","Lightle R","Lyne SB","Carrion-Penagos J","Ji Y","Shkoukani A","Carroll T"],"additional_accession":[]},"is_claimable":false,"name":"Perfusion and permeability as diagnostic biomarkers of cavernous angioma with symptomatic hemorrhage.","description":"Cavernous angiomas with symptomatic hemorrhage (CASH) have a high risk of rebleeding, and hence an accurate diagnosis is needed. With blood flow and vascular leak as established mechanisms, we analyzed perfusion and permeability derivations of dynamic contrast-enhanced quantitative perfusion (DCEQP) MRI in 745 lesions of 205 consecutive patients. Thirteen respective derivations of lesional perfusion and permeability were compared between lesions that bled within a year prior to imaging (N = 86), versus non-CASH (N = 659) using machine learning and univariate analyses. Based on logistic regression and minimizing the Bayesian information criterion (BIC), the best diagnostic biomarker of CASH within the prior year included brainstem lesion location, sporadic genotype, perfusion skewness, and high-perfusion cluster area (BIC = 414.9, sensitivity = 74%, specificity = 87%). Adding a diagnostic plasma protein biomarker enhanced sensitivity to 100% and specificity to 85%. A slightly modified derivation achieved similar accuracy (BIC = 321.6, sensitivity = 80%, specificity = 82%) in the cohort where CASH occurred 3-12 months prior to imaging after signs of hemorrhage would have disappeared on conventional MRI sequences. Adding the same plasma biomarker enhanced sensitivity to 100% and specificity to 87%. Lesional blood flow on DCEQP may distinguish CASH after hemorrhagic signs on conventional MRI have disappeared and are enhanced in combination with a plasma biomarker.","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Nov","modification":"2026-05-09T03:08:52.553Z","creation":"2025-04-20T03:09:00.545Z"},"accession":"S-EPMC8756480","cross_references":{"pubmed":["34039038"],"doi":["10.1177/0271678X211020587","10.1177/0271678x211020587"]}}